Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
90 American society of anesthesiology (ASA) physical status I and II patients undergoing general anesthesia for elective surgery will be included in the study. Patients will be randomized into three groups. Group E will receive esmolol (1 mg/kg), Group IL lidocaine (0.5 mg/kg)and Group C placebo(NaCl 0.9%, 5 mL), followed by a 0.05 mg/kg rocuronium. After intravenous induction with propofol, adequate muscle relaxation for intubation will be received by 0.5 mg/kg rocuronium.
Patients will be observed after injection of rocuronium 0.05mg/kg, then immediately asked if they have pain in the arm. The response are assessed; discomfort, pain, and withdrawal of the hand are recorded and graded using a 4-point scale (none, mild, moderate, or severe). After the intubating dose of rocuronium, withdrawal reactions are scored as follows: (a) no pain response, (b)pain limited to the wrist, (c) pain limited to the elbow/shoulder, or (d) generalized pain response.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| brevibloc (esmolol) | Experimental | Group E will receive esmolol (1 mg/kg), Group L lidocaine (0.5 mg/kg)and Group C placebo(NaCl 0.9%, 5 mL) |
|
| Aritmal (Lidocaine) | Active Comparator | Group E: esmolol (1 mg/kg) Group L: lidocaine (0.5 mg/kg) Group C: placebo(NaCl 0.9%, 5 mL) |
|
| Placebo (NaCl 0.9%, 5 ml) | Placebo Comparator | Group E: esmolol (1 mg/kg) Group L: lidocaine (0.5 mg/kg) Group C: placebo(NaCl 0.9%, 5 mL) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Lidocaine | Drug | Group L lidocaine (0.5 mg/kg), (rocuronium) (0.05mg/kg). |
|
| Measure | Description | Time Frame |
|---|---|---|
| The injection pain due to rocuronium | Pain will be recorded and graded using a 4-point scale (none, mild, moderate, or severe). | 1 month |
| Measure | Description | Time Frame |
|---|---|---|
| Score on pain due to injection of rocuronium | Withdrawal reactions are scored as follows: (a) no pain response, (b)pain limited to the wrist, (c) pain limited to the elbow/shoulder, or (d) generalized pain response. | 1 month |
| Measure | Description | Time Frame |
|---|---|---|
| To assess patient satisfaction | 1 Month |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Fakelma 05327079113 | Diskapi Teaching and Research Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Diskapi Teaching and Research Hospital | Ankara | Altindag | Turkey (Türkiye) |
Not provided
| ID | Term |
|---|---|
| D008012 | Lidocaine |
| C036604 | esmolol |
| D000077123 | Rocuronium |
| ID | Term |
|---|---|
| D000083 | Acetanilides |
| D000813 | Anilides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D000814 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Esmolol | Drug | Group E: esmolol (1 mg/kg), (rocuronium) (0.05mg/kg) |
|
|
| rocuronium | Drug | 0.05 mg/kg rocuronium |
|
| Placebo | Drug | Group C: Placebo (NaCl 0.9%, 5 ml), (rocuronium) (0.05mg/kg) |
|
| Aniline Compounds |
| D000588 | Amines |
| D000732 | Androstanols |
| D000731 | Androstanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |